<?xml version="1.0" encoding="UTF-8" ?>
<oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title>A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients</dc:title>
<dc:creator>Moreno, Gerard</dc:creator>
<dc:creator>Marin Corral, Judith</dc:creator>
<dc:creator>Rodríguez, Alejandro</dc:creator>
<dc:creator>COVID-19 SEMICYUC Working Group</dc:creator>
<dc:subject>COVID-19</dc:subject>
<dc:subject>Corticosteroids</dc:subject>
<dc:subject>ICU Mortality</dc:subject>
<dc:subject>Phenotypes</dc:subject>
<dc:subject>SARS-CoV2-pneumonia</dc:subject>
<dc:subject>Unsupervised clustering</dc:subject>
<dc:description>Objective: To determine if the use of corticosteroids was associated with Intensive Care Unit (ICU) mortality among whole population and pre-specified clinical phenotypes. Design: A secondary analysis derived from multicenter, observational study. Setting: Critical Care Units. Patients: Adult critically ill patients with confirmed COVID-19 disease admitted to 63 ICUs in Spain. Interventions: Corticosteroids vs. no corticosteroids. Main variables of interest: Three phenotypes were derived by non-supervised clustering analysis from whole population and classified as (A: severe, B: critical and C: life-threatening). We performed a multivariate analysis after propensity optimal full matching (PS) for whole population and weighted Cox regression (HR) and Fine-Gray analysis (sHR) to assess the impact of corticosteroids on ICU mortality according to the whole population and distinctive patient clinical phenotypes. Results: A total of 2017 patients were analyzed, 1171 (58%) with corticosteroids. After PS, corticosteroids were shown not to be associated with ICU mortality (OR: 1.0; 95% CI: 0.98–1.15). Corticosteroids were administered in 298/537 (55.5%) patients of “A” phenotype and their use was not associated with ICU mortality (HR = 0.85 [0.55–1.33]). A total of 338/623 (54.2%) patients in “B” phenotype received corticosteroids. No effect of corticosteroids on ICU mortality was observed when HR was performed (0.72 [0.49–1.05]). Finally, 535/857 (62.4%) patients in “C” phenotype received corticosteroids. In this phenotype HR (0.75 [0.58–0.98]) and sHR (0.79 [0.63–0.98]) suggest a protective effect of corticosteroids on ICU mortality. Conclusion: Our finding warns against the widespread use of corticosteroids in all critically ill patients with COVID-19 at moderate dose. Only patients with the highest inflammatory levels could benefit from steroid treatment.</dc:description>
<dc:date>2023</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:type>info:eu-repo/semantics/acceptedVersion</dc:type>
<dc:identifier>Moreno G, Ruiz-Botella M, Martín-Loeches I, Alvarez JG, Herrera MJ, Bodí M, et al. A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients. Med Intensiva. 2023 Jan; 47(1): 23-33. DOI: 10.1016/j.medin.2021.10.002</dc:identifier>
<dc:identifier>0210-5691</dc:identifier>
<dc:identifier>http://hdl.handle.net/10230/53634</dc:identifier>
<dc:identifier>http://dx.doi.org/10.1016/j.medin.2021.10.002</dc:identifier>
<dc:language>eng</dc:language>
<dc:rights>© Elsevier http://dx.doi.org/10.1016/j.medin.2021.10.002</dc:rights>
<dc:rights>info:eu-repo/semantics/embargoedAccess</dc:rights>
<dc:format>application/pdf</dc:format>
<dc:publisher>Elsevier</dc:publisher>
</oai_dc:dc>
<?xml version="1.0" encoding="UTF-8" ?>
<d:DIDL schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
<d:Item id="hdl_10230_53634">
<d:Descriptor>
<d:Statement mimeType="application/xml; charset=utf-8">
<dii:Identifier schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:10230/53634</dii:Identifier>
</d:Statement>
</d:Descriptor>
<d:Descriptor>
<d:Statement mimeType="application/xml; charset=utf-8">
<oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title>A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients</dc:title>
<dc:creator>Moreno, Gerard</dc:creator>
<dc:creator>Marin Corral, Judith</dc:creator>
<dc:creator>Rodríguez, Alejandro</dc:creator>
<dc:creator>COVID-19 SEMICYUC Working Group</dc:creator>
<dc:description>Objective: To determine if the use of corticosteroids was associated with Intensive Care Unit (ICU) mortality among whole population and pre-specified clinical phenotypes. Design: A secondary analysis derived from multicenter, observational study. Setting: Critical Care Units. Patients: Adult critically ill patients with confirmed COVID-19 disease admitted to 63 ICUs in Spain. Interventions: Corticosteroids vs. no corticosteroids. Main variables of interest: Three phenotypes were derived by non-supervised clustering analysis from whole population and classified as (A: severe, B: critical and C: life-threatening). We performed a multivariate analysis after propensity optimal full matching (PS) for whole population and weighted Cox regression (HR) and Fine-Gray analysis (sHR) to assess the impact of corticosteroids on ICU mortality according to the whole population and distinctive patient clinical phenotypes. Results: A total of 2017 patients were analyzed, 1171 (58%) with corticosteroids. After PS, corticosteroids were shown not to be associated with ICU mortality (OR: 1.0; 95% CI: 0.98–1.15). Corticosteroids were administered in 298/537 (55.5%) patients of “A” phenotype and their use was not associated with ICU mortality (HR = 0.85 [0.55–1.33]). A total of 338/623 (54.2%) patients in “B” phenotype received corticosteroids. No effect of corticosteroids on ICU mortality was observed when HR was performed (0.72 [0.49–1.05]). Finally, 535/857 (62.4%) patients in “C” phenotype received corticosteroids. In this phenotype HR (0.75 [0.58–0.98]) and sHR (0.79 [0.63–0.98]) suggest a protective effect of corticosteroids on ICU mortality. Conclusion: Our finding warns against the widespread use of corticosteroids in all critically ill patients with COVID-19 at moderate dose. Only patients with the highest inflammatory levels could benefit from steroid treatment.</dc:description>
<dc:date>2022-06-29T07:06:15Z</dc:date>
<dc:date>2023</dc:date>
<dc:date>info:eu-repo/date/embargoEnd/2022-10-26</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:identifier>Moreno G, Ruiz-Botella M, Martín-Loeches I, Alvarez JG, Herrera MJ, Bodí M, et al. A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients. Med Intensiva. 2023 Jan; 47(1): 23-33. DOI: 10.1016/j.medin.2021.10.002</dc:identifier>
<dc:identifier>0210-5691</dc:identifier>
<dc:identifier>http://hdl.handle.net/10230/53634</dc:identifier>
<dc:identifier>http://dx.doi.org/10.1016/j.medin.2021.10.002</dc:identifier>
<dc:language>eng</dc:language>
<dc:rights>info:eu-repo/semantics/embargoedAccess</dc:rights>
<dc:rights>© Elsevier http://dx.doi.org/10.1016/j.medin.2021.10.002</dc:rights>
<dc:publisher>Elsevier</dc:publisher>
</oai_dc:dc>
</d:Statement>
</d:Descriptor>
<d:Component id="10230_53634_1">
</d:Component>
</d:Item>
</d:DIDL>
<?xml version="1.0" encoding="UTF-8" ?>
<dim:dim schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
<dim:field element="contributor" mdschema="dc" qualifier="author">Moreno, Gerard</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Marin Corral, Judith</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Rodríguez, Alejandro</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">COVID-19 SEMICYUC Working Group</dim:field>
<dim:field element="date" mdschema="dc" qualifier="accessioned">2022-06-29T07:06:15Z</dim:field>
<dim:field element="date" mdschema="dc" qualifier="issued">2023</dim:field>
<dim:field element="date" mdschema="dc" qualifier="embargoEnd">info:eu-repo/date/embargoEnd/2022-10-26</dim:field>
<dim:field element="identifier" mdschema="dc" qualifier="citation">Moreno G, Ruiz-Botella M, Martín-Loeches I, Alvarez JG, Herrera MJ, Bodí M, et al. A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients. Med Intensiva. 2023 Jan; 47(1): 23-33. DOI: 10.1016/j.medin.2021.10.002</dim:field>
<dim:field element="identifier" mdschema="dc" qualifier="issn">0210-5691</dim:field>
<dim:field element="identifier" mdschema="dc" qualifier="uri">http://hdl.handle.net/10230/53634</dim:field>
<dim:field element="identifier" mdschema="dc" qualifier="doi">http://dx.doi.org/10.1016/j.medin.2021.10.002</dim:field>
<dim:field element="description" mdschema="dc" qualifier="abstract">Objective: To determine if the use of corticosteroids was associated with Intensive Care Unit (ICU) mortality among whole population and pre-specified clinical phenotypes. Design: A secondary analysis derived from multicenter, observational study. Setting: Critical Care Units. Patients: Adult critically ill patients with confirmed COVID-19 disease admitted to 63 ICUs in Spain. Interventions: Corticosteroids vs. no corticosteroids. Main variables of interest: Three phenotypes were derived by non-supervised clustering analysis from whole population and classified as (A: severe, B: critical and C: life-threatening). We performed a multivariate analysis after propensity optimal full matching (PS) for whole population and weighted Cox regression (HR) and Fine-Gray analysis (sHR) to assess the impact of corticosteroids on ICU mortality according to the whole population and distinctive patient clinical phenotypes. Results: A total of 2017 patients were analyzed, 1171 (58%) with corticosteroids. After PS, corticosteroids were shown not to be associated with ICU mortality (OR: 1.0; 95% CI: 0.98–1.15). Corticosteroids were administered in 298/537 (55.5%) patients of “A” phenotype and their use was not associated with ICU mortality (HR = 0.85 [0.55–1.33]). A total of 338/623 (54.2%) patients in “B” phenotype received corticosteroids. No effect of corticosteroids on ICU mortality was observed when HR was performed (0.72 [0.49–1.05]). Finally, 535/857 (62.4%) patients in “C” phenotype received corticosteroids. In this phenotype HR (0.75 [0.58–0.98]) and sHR (0.79 [0.63–0.98]) suggest a protective effect of corticosteroids on ICU mortality. Conclusion: Our finding warns against the widespread use of corticosteroids in all critically ill patients with COVID-19 at moderate dose. Only patients with the highest inflammatory levels could benefit from steroid treatment.</dim:field>
<dim:field element="description" lang="en" mdschema="dc" qualifier="provenance">Made available in DSpace on 2022-06-29T07:06:15Z (GMT). No. of bitstreams: 1 moreno-mei-adif.pdf: 797198 bytes, checksum: 56849396de860830e4e708ecce55e641 (MD5) Previous issue date: 2021</dim:field>
<dim:field element="format" mdschema="dc" qualifier="mimetype">application/pdf</dim:field>
<dim:field element="language" mdschema="dc" qualifier="iso">eng</dim:field>
<dim:field element="publisher" mdschema="dc">Elsevier</dim:field>
<dim:field element="rights" mdschema="dc">© Elsevier http://dx.doi.org/10.1016/j.medin.2021.10.002</dim:field>
<dim:field element="rights" mdschema="dc" qualifier="accessRights">info:eu-repo/semantics/embargoedAccess</dim:field>
<dim:field element="title" mdschema="dc">A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients</dim:field>
<dim:field element="type" mdschema="dc">info:eu-repo/semantics/article</dim:field>
<dim:field element="type" mdschema="dc" qualifier="version">info:eu-repo/semantics/acceptedVersion</dim:field>
<dim:field element="subject" mdschema="dc" qualifier="keyword">COVID-19</dim:field>
<dim:field element="subject" mdschema="dc" qualifier="keyword">Corticosteroids</dim:field>
<dim:field element="subject" mdschema="dc" qualifier="keyword">ICU Mortality</dim:field>
<dim:field element="subject" mdschema="dc" qualifier="keyword">Phenotypes</dim:field>
<dim:field element="subject" mdschema="dc" qualifier="keyword">SARS-CoV2-pneumonia</dim:field>
<dim:field element="subject" mdschema="dc" qualifier="keyword">Unsupervised clustering</dim:field>
<dim:field element="embargo" mdschema="dc" qualifier="liftdate">2022-10-26</dim:field>
</dim:dim>
<?xml version="1.0" encoding="UTF-8" ?>
<thesis schemaLocation="http://www.ndltd.org/standards/metadata/etdms/1.0/ http://www.ndltd.org/standards/metadata/etdms/1.0/etdms.xsd">
<title>A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients</title>
<creator>Moreno, Gerard</creator>
<creator>Marin Corral, Judith</creator>
<creator>Rodríguez, Alejandro</creator>
<creator>COVID-19 SEMICYUC Working Group</creator>
<description>Objective: To determine if the use of corticosteroids was associated with Intensive Care Unit (ICU) mortality among whole population and pre-specified clinical phenotypes. Design: A secondary analysis derived from multicenter, observational study. Setting: Critical Care Units. Patients: Adult critically ill patients with confirmed COVID-19 disease admitted to 63 ICUs in Spain. Interventions: Corticosteroids vs. no corticosteroids. Main variables of interest: Three phenotypes were derived by non-supervised clustering analysis from whole population and classified as (A: severe, B: critical and C: life-threatening). We performed a multivariate analysis after propensity optimal full matching (PS) for whole population and weighted Cox regression (HR) and Fine-Gray analysis (sHR) to assess the impact of corticosteroids on ICU mortality according to the whole population and distinctive patient clinical phenotypes. Results: A total of 2017 patients were analyzed, 1171 (58%) with corticosteroids. After PS, corticosteroids were shown not to be associated with ICU mortality (OR: 1.0; 95% CI: 0.98–1.15). Corticosteroids were administered in 298/537 (55.5%) patients of “A” phenotype and their use was not associated with ICU mortality (HR = 0.85 [0.55–1.33]). A total of 338/623 (54.2%) patients in “B” phenotype received corticosteroids. No effect of corticosteroids on ICU mortality was observed when HR was performed (0.72 [0.49–1.05]). Finally, 535/857 (62.4%) patients in “C” phenotype received corticosteroids. In this phenotype HR (0.75 [0.58–0.98]) and sHR (0.79 [0.63–0.98]) suggest a protective effect of corticosteroids on ICU mortality. Conclusion: Our finding warns against the widespread use of corticosteroids in all critically ill patients with COVID-19 at moderate dose. Only patients with the highest inflammatory levels could benefit from steroid treatment.</description>
<date>2022-06-29</date>
<date>2023</date>
<date>info:eu-re</date>
<type>info:eu-repo/semantics/article</type>
<identifier>Moreno G, Ruiz-Botella M, Martín-Loeches I, Alvarez JG, Herrera MJ, Bodí M, et al. A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients. Med Intensiva. 2023 Jan; 47(1): 23-33. DOI: 10.1016/j.medin.2021.10.002</identifier>
<identifier>0210-5691</identifier>
<identifier>http://hdl.handle.net/10230/53634</identifier>
<identifier>http://dx.doi.org/10.1016/j.medin.2021.10.002</identifier>
<language>eng</language>
<rights>info:eu-repo/semantics/embargoedAccess</rights>
<rights>© Elsevier http://dx.doi.org/10.1016/j.medin.2021.10.002</rights>
<publisher>Elsevier</publisher>
</thesis>
<?xml version="1.0" encoding="UTF-8" ?>
<record schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
<leader>00925njm 22002777a 4500</leader>
<datafield ind1=" " ind2=" " tag="042">
<subfield code="a">dc</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Moreno, Gerard</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Marin Corral, Judith</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Rodríguez, Alejandro</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">COVID-19 SEMICYUC Working Group</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="260">
<subfield code="c">2023</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="520">
<subfield code="a">Objective: To determine if the use of corticosteroids was associated with Intensive Care Unit (ICU) mortality among whole population and pre-specified clinical phenotypes. Design: A secondary analysis derived from multicenter, observational study. Setting: Critical Care Units. Patients: Adult critically ill patients with confirmed COVID-19 disease admitted to 63 ICUs in Spain. Interventions: Corticosteroids vs. no corticosteroids. Main variables of interest: Three phenotypes were derived by non-supervised clustering analysis from whole population and classified as (A: severe, B: critical and C: life-threatening). We performed a multivariate analysis after propensity optimal full matching (PS) for whole population and weighted Cox regression (HR) and Fine-Gray analysis (sHR) to assess the impact of corticosteroids on ICU mortality according to the whole population and distinctive patient clinical phenotypes. Results: A total of 2017 patients were analyzed, 1171 (58%) with corticosteroids. After PS, corticosteroids were shown not to be associated with ICU mortality (OR: 1.0; 95% CI: 0.98–1.15). Corticosteroids were administered in 298/537 (55.5%) patients of “A” phenotype and their use was not associated with ICU mortality (HR = 0.85 [0.55–1.33]). A total of 338/623 (54.2%) patients in “B” phenotype received corticosteroids. No effect of corticosteroids on ICU mortality was observed when HR was performed (0.72 [0.49–1.05]). Finally, 535/857 (62.4%) patients in “C” phenotype received corticosteroids. In this phenotype HR (0.75 [0.58–0.98]) and sHR (0.79 [0.63–0.98]) suggest a protective effect of corticosteroids on ICU mortality. Conclusion: Our finding warns against the widespread use of corticosteroids in all critically ill patients with COVID-19 at moderate dose. Only patients with the highest inflammatory levels could benefit from steroid treatment.</subfield>
</datafield>
<datafield ind1="8" ind2=" " tag="024">
<subfield code="a">Moreno G, Ruiz-Botella M, Martín-Loeches I, Alvarez JG, Herrera MJ, Bodí M, et al. A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients. Med Intensiva. 2023 Jan; 47(1): 23-33. DOI: 10.1016/j.medin.2021.10.002</subfield>
</datafield>
<datafield ind1="8" ind2=" " tag="024">
<subfield code="a">0210-5691</subfield>
</datafield>
<datafield ind1="8" ind2=" " tag="024">
<subfield code="a">http://hdl.handle.net/10230/53634</subfield>
</datafield>
<datafield ind1="8" ind2=" " tag="024">
<subfield code="a">http://dx.doi.org/10.1016/j.medin.2021.10.002</subfield>
</datafield>
<datafield ind1="0" ind2="0" tag="245">
<subfield code="a">A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients</subfield>
</datafield>
</record>
<?xml version="1.0" encoding="UTF-8" ?>
<mets ID=" DSpace_ITEM_10230-53634" OBJID=" hdl:10230/53634" PROFILE="DSpace METS SIP Profile 1.0" TYPE="DSpace ITEM" schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd">
<metsHdr CREATEDATE="2023-04-12T01:49:36Z">
<agent ROLE="CUSTODIAN" TYPE="ORGANIZATION">
<name>Repositori digital de la UPF</name>
</agent>
</metsHdr>
<dmdSec ID="DMD_10230_53634">
<mdWrap MDTYPE="MODS">
<xmlData schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:mods schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Moreno, Gerard</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Marin Corral, Judith</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Rodríguez, Alejandro</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>COVID-19 SEMICYUC Working Group</mods:namePart>
</mods:name>
<mods:extension>
<mods:dateAccessioned encoding="iso8601">2022-06-29T07:06:15Z</mods:dateAccessioned>
</mods:extension>
<mods:originInfo>
<mods:dateIssued encoding="iso8601">2023</mods:dateIssued>
</mods:originInfo>
<mods:identifier type="citation">Moreno G, Ruiz-Botella M, Martín-Loeches I, Alvarez JG, Herrera MJ, Bodí M, et al. A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients. Med Intensiva. 2023 Jan; 47(1): 23-33. DOI: 10.1016/j.medin.2021.10.002</mods:identifier>
<mods:identifier type="issn">0210-5691</mods:identifier>
<mods:identifier type="uri">http://hdl.handle.net/10230/53634</mods:identifier>
<mods:identifier type="doi">http://dx.doi.org/10.1016/j.medin.2021.10.002</mods:identifier>
<mods:abstract>Objective: To determine if the use of corticosteroids was associated with Intensive Care Unit (ICU) mortality among whole population and pre-specified clinical phenotypes. Design: A secondary analysis derived from multicenter, observational study. Setting: Critical Care Units. Patients: Adult critically ill patients with confirmed COVID-19 disease admitted to 63 ICUs in Spain. Interventions: Corticosteroids vs. no corticosteroids. Main variables of interest: Three phenotypes were derived by non-supervised clustering analysis from whole population and classified as (A: severe, B: critical and C: life-threatening). We performed a multivariate analysis after propensity optimal full matching (PS) for whole population and weighted Cox regression (HR) and Fine-Gray analysis (sHR) to assess the impact of corticosteroids on ICU mortality according to the whole population and distinctive patient clinical phenotypes. Results: A total of 2017 patients were analyzed, 1171 (58%) with corticosteroids. After PS, corticosteroids were shown not to be associated with ICU mortality (OR: 1.0; 95% CI: 0.98–1.15). Corticosteroids were administered in 298/537 (55.5%) patients of “A” phenotype and their use was not associated with ICU mortality (HR = 0.85 [0.55–1.33]). A total of 338/623 (54.2%) patients in “B” phenotype received corticosteroids. No effect of corticosteroids on ICU mortality was observed when HR was performed (0.72 [0.49–1.05]). Finally, 535/857 (62.4%) patients in “C” phenotype received corticosteroids. In this phenotype HR (0.75 [0.58–0.98]) and sHR (0.79 [0.63–0.98]) suggest a protective effect of corticosteroids on ICU mortality. Conclusion: Our finding warns against the widespread use of corticosteroids in all critically ill patients with COVID-19 at moderate dose. Only patients with the highest inflammatory levels could benefit from steroid treatment.</mods:abstract>
<mods:language>
<mods:languageTerm authority="rfc3066">eng</mods:languageTerm>
</mods:language>
<mods:accessCondition type="useAndReproduction">© Elsevier http://dx.doi.org/10.1016/j.medin.2021.10.002</mods:accessCondition>
<mods:titleInfo>
<mods:title>A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients</mods:title>
</mods:titleInfo>
<mods:genre>info:eu-repo/semantics/article</mods:genre>
</mods:mods>
</xmlData>
</mdWrap>
</dmdSec>
<amdSec ID="FO_10230_53634_1">
<techMD ID="TECH_O_10230_53634_1">
<mdWrap MDTYPE="PREMIS">
<xmlData schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">
<premis:premis>
<premis:object>
<premis:objectIdentifier>
<premis:objectIdentifierType>URL</premis:objectIdentifierType>
<premis:objectIdentifierValue>http://repositori.upf.edu/bitstream/10230/53634/1/moreno-mei-adif.pdf</premis:objectIdentifierValue>
</premis:objectIdentifier>
<premis:objectCategory>File</premis:objectCategory>
<premis:objectCharacteristics>
<premis:fixity>
<premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>
<premis:messageDigest>56849396de860830e4e708ecce55e641</premis:messageDigest>
</premis:fixity>
<premis:size>797198</premis:size>
<premis:format>
<premis:formatDesignation>
<premis:formatName>application/pdf</premis:formatName>
</premis:formatDesignation>
</premis:format>
</premis:objectCharacteristics>
<premis:originalName>moreno-mei-adif.pdf</premis:originalName>
</premis:object>
</premis:premis>
</xmlData>
</mdWrap>
</techMD>
</amdSec>
<amdSec ID="FT_10230_53634_2">
<techMD ID="TECH_T_10230_53634_2">
<mdWrap MDTYPE="PREMIS">
<xmlData schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">
<premis:premis>
<premis:object>
<premis:objectIdentifier>
<premis:objectIdentifierType>URL</premis:objectIdentifierType>
<premis:objectIdentifierValue>http://repositori.upf.edu/bitstream/10230/53634/2/moreno-mei-adif.pdf.txt</premis:objectIdentifierValue>
</premis:objectIdentifier>
<premis:objectCategory>File</premis:objectCategory>
<premis:objectCharacteristics>
<premis:fixity>
<premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>
<premis:messageDigest>840d423b5ad467fd5867e5c2282bb06f</premis:messageDigest>
</premis:fixity>
<premis:size>52424</premis:size>
<premis:format>
<premis:formatDesignation>
<premis:formatName>text/plain</premis:formatName>
</premis:formatDesignation>
</premis:format>
</premis:objectCharacteristics>
<premis:originalName>moreno-mei-adif.pdf.txt</premis:originalName>
</premis:object>
</premis:premis>
</xmlData>
</mdWrap>
</techMD>
</amdSec>
<fileSec>
<fileGrp USE="ORIGINAL">
<file ADMID="FO_10230_53634_1" CHECKSUM="56849396de860830e4e708ecce55e641" CHECKSUMTYPE="MD5" GROUPID="GROUP_BITSTREAM_10230_53634_1" ID="BITSTREAM_ORIGINAL_10230_53634_1" MIMETYPE="application/pdf" SEQ="1" SIZE="797198">
</file>
</fileGrp>
<fileGrp USE="TEXT">
<file ADMID="FT_10230_53634_2" CHECKSUM="840d423b5ad467fd5867e5c2282bb06f" CHECKSUMTYPE="MD5" GROUPID="GROUP_BITSTREAM_10230_53634_2" ID="BITSTREAM_TEXT_10230_53634_2" MIMETYPE="text/plain" SEQ="2" SIZE="52424">
</file>
</fileGrp>
</fileSec>
<structMap LABEL="DSpace Object" TYPE="LOGICAL">
<div ADMID="DMD_10230_53634" TYPE="DSpace Object Contents">
<div TYPE="DSpace BITSTREAM">
</div>
</div>
</structMap>
</mets>
<?xml version="1.0" encoding="UTF-8" ?>
<mods:mods schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:name>
<mods:namePart>Moreno, Gerard</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Marin Corral, Judith</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Rodríguez, Alejandro</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>COVID-19 SEMICYUC Working Group</mods:namePart>
</mods:name>
<mods:extension>
<mods:dateAvailable encoding="iso8601">2022-06-29T07:06:15Z</mods:dateAvailable>
</mods:extension>
<mods:originInfo>
<mods:dateIssued encoding="iso8601">2023</mods:dateIssued>
</mods:originInfo>
<mods:identifier type="citation">Moreno G, Ruiz-Botella M, Martín-Loeches I, Alvarez JG, Herrera MJ, Bodí M, et al. A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients. Med Intensiva. 2023 Jan; 47(1): 23-33. DOI: 10.1016/j.medin.2021.10.002</mods:identifier>
<mods:identifier type="issn">0210-5691</mods:identifier>
<mods:identifier type="uri">http://hdl.handle.net/10230/53634</mods:identifier>
<mods:identifier type="doi">http://dx.doi.org/10.1016/j.medin.2021.10.002</mods:identifier>
<mods:abstract>Objective: To determine if the use of corticosteroids was associated with Intensive Care Unit (ICU) mortality among whole population and pre-specified clinical phenotypes. Design: A secondary analysis derived from multicenter, observational study. Setting: Critical Care Units. Patients: Adult critically ill patients with confirmed COVID-19 disease admitted to 63 ICUs in Spain. Interventions: Corticosteroids vs. no corticosteroids. Main variables of interest: Three phenotypes were derived by non-supervised clustering analysis from whole population and classified as (A: severe, B: critical and C: life-threatening). We performed a multivariate analysis after propensity optimal full matching (PS) for whole population and weighted Cox regression (HR) and Fine-Gray analysis (sHR) to assess the impact of corticosteroids on ICU mortality according to the whole population and distinctive patient clinical phenotypes. Results: A total of 2017 patients were analyzed, 1171 (58%) with corticosteroids. After PS, corticosteroids were shown not to be associated with ICU mortality (OR: 1.0; 95% CI: 0.98–1.15). Corticosteroids were administered in 298/537 (55.5%) patients of “A” phenotype and their use was not associated with ICU mortality (HR = 0.85 [0.55–1.33]). A total of 338/623 (54.2%) patients in “B” phenotype received corticosteroids. No effect of corticosteroids on ICU mortality was observed when HR was performed (0.72 [0.49–1.05]). Finally, 535/857 (62.4%) patients in “C” phenotype received corticosteroids. In this phenotype HR (0.75 [0.58–0.98]) and sHR (0.79 [0.63–0.98]) suggest a protective effect of corticosteroids on ICU mortality. Conclusion: Our finding warns against the widespread use of corticosteroids in all critically ill patients with COVID-19 at moderate dose. Only patients with the highest inflammatory levels could benefit from steroid treatment.</mods:abstract>
<mods:language>
<mods:languageTerm>eng</mods:languageTerm>
</mods:language>
<mods:accessCondition type="useAndReproduction">info:eu-repo/semantics/embargoedAccess</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">© Elsevier http://dx.doi.org/10.1016/j.medin.2021.10.002</mods:accessCondition>
<mods:titleInfo>
<mods:title>A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients</mods:title>
</mods:titleInfo>
<mods:genre>info:eu-repo/semantics/article</mods:genre>
</mods:mods>
<?xml version="1.0" encoding="UTF-8" ?>
<atom:entry schemaLocation="http://www.w3.org/2005/Atom http://www.kbcafe.com/rss/atom.xsd.xml">
<atom:id>http://oai-repositori.upf.edu/oai/metadata/handle/10230/53634/ore.xml</atom:id>
<atom:updated>2022-06-29T07:06:15Z</atom:updated>
<atom:source>
<atom:generator>Repositori digital de la UPF</atom:generator>
</atom:source>
<atom:title>A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients</atom:title>
<atom:author>
<atom:name>Moreno, Gerard</atom:name>
</atom:author>
<atom:author>
<atom:name>Marin Corral, Judith</atom:name>
</atom:author>
<atom:author>
<atom:name>Rodríguez, Alejandro</atom:name>
</atom:author>
<atom:author>
<atom:name>COVID-19 SEMICYUC Working Group</atom:name>
</atom:author>
<oreatom:triples>
<rdf:Description about="http://oai-repositori.upf.edu/oai/metadata/handle/10230/53634/ore.xml#atom">
<dcterms:modified>2022-06-29T07:06:15Z</dcterms:modified>
</rdf:Description>
<rdf:Description about="http://repositori.upf.edu/bitstream/10230/53634/3/moreno-mei-adif.pdf.jpg">
<dcterms:description>THUMBNAIL</dcterms:description>
</rdf:Description>
<rdf:Description about="http://repositori.upf.edu/bitstream/10230/53634/2/moreno-mei-adif.pdf.txt">
<dcterms:description>TEXT</dcterms:description>
</rdf:Description>
<rdf:Description about="http://repositori.upf.edu/bitstream/10230/53634/1/moreno-mei-adif.pdf">
<dcterms:description>ORIGINAL</dcterms:description>
</rdf:Description>
</oreatom:triples>
</atom:entry>
<?xml version="1.0" encoding="UTF-8" ?>
<qdc:qualifieddc schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
<dc:title>A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients</dc:title>
<dc:creator>Moreno, Gerard</dc:creator>
<dc:creator>Marin Corral, Judith</dc:creator>
<dc:creator>Rodríguez, Alejandro</dc:creator>
<dc:creator>COVID-19 SEMICYUC Working Group</dc:creator>
<dcterms:abstract>Objective: To determine if the use of corticosteroids was associated with Intensive Care Unit (ICU) mortality among whole population and pre-specified clinical phenotypes. Design: A secondary analysis derived from multicenter, observational study. Setting: Critical Care Units. Patients: Adult critically ill patients with confirmed COVID-19 disease admitted to 63 ICUs in Spain. Interventions: Corticosteroids vs. no corticosteroids. Main variables of interest: Three phenotypes were derived by non-supervised clustering analysis from whole population and classified as (A: severe, B: critical and C: life-threatening). We performed a multivariate analysis after propensity optimal full matching (PS) for whole population and weighted Cox regression (HR) and Fine-Gray analysis (sHR) to assess the impact of corticosteroids on ICU mortality according to the whole population and distinctive patient clinical phenotypes. Results: A total of 2017 patients were analyzed, 1171 (58%) with corticosteroids. After PS, corticosteroids were shown not to be associated with ICU mortality (OR: 1.0; 95% CI: 0.98–1.15). Corticosteroids were administered in 298/537 (55.5%) patients of “A” phenotype and their use was not associated with ICU mortality (HR = 0.85 [0.55–1.33]). A total of 338/623 (54.2%) patients in “B” phenotype received corticosteroids. No effect of corticosteroids on ICU mortality was observed when HR was performed (0.72 [0.49–1.05]). Finally, 535/857 (62.4%) patients in “C” phenotype received corticosteroids. In this phenotype HR (0.75 [0.58–0.98]) and sHR (0.79 [0.63–0.98]) suggest a protective effect of corticosteroids on ICU mortality. Conclusion: Our finding warns against the widespread use of corticosteroids in all critically ill patients with COVID-19 at moderate dose. Only patients with the highest inflammatory levels could benefit from steroid treatment.</dcterms:abstract>
<dc:date>2023</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:identifier>Moreno G, Ruiz-Botella M, Martín-Loeches I, Alvarez JG, Herrera MJ, Bodí M, et al. A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients. Med Intensiva. 2023 Jan; 47(1): 23-33. DOI: 10.1016/j.medin.2021.10.002</dc:identifier>
<dc:identifier>0210-5691</dc:identifier>
<dc:identifier>http://hdl.handle.net/10230/53634</dc:identifier>
<dc:identifier>http://dx.doi.org/10.1016/j.medin.2021.10.002</dc:identifier>
<dc:language>eng</dc:language>
<dc:rights>info:eu-repo/semantics/embargoedAccess</dc:rights>
<dc:rights>© Elsevier http://dx.doi.org/10.1016/j.medin.2021.10.002</dc:rights>
<dc:publisher>Elsevier</dc:publisher>
</qdc:qualifieddc>
<?xml version="1.0" encoding="UTF-8" ?>
<rdf:RDF schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
<ow:Publication about="oai:repositori.upf.edu:10230/53634">
<dc:title>A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients</dc:title>
<dc:creator>Moreno, Gerard</dc:creator>
<dc:creator>Marin Corral, Judith</dc:creator>
<dc:creator>Rodríguez, Alejandro</dc:creator>
<dc:creator>COVID-19 SEMICYUC Working Group</dc:creator>
<dc:description>Objective: To determine if the use of corticosteroids was associated with Intensive Care Unit (ICU) mortality among whole population and pre-specified clinical phenotypes. Design: A secondary analysis derived from multicenter, observational study. Setting: Critical Care Units. Patients: Adult critically ill patients with confirmed COVID-19 disease admitted to 63 ICUs in Spain. Interventions: Corticosteroids vs. no corticosteroids. Main variables of interest: Three phenotypes were derived by non-supervised clustering analysis from whole population and classified as (A: severe, B: critical and C: life-threatening). We performed a multivariate analysis after propensity optimal full matching (PS) for whole population and weighted Cox regression (HR) and Fine-Gray analysis (sHR) to assess the impact of corticosteroids on ICU mortality according to the whole population and distinctive patient clinical phenotypes. Results: A total of 2017 patients were analyzed, 1171 (58%) with corticosteroids. After PS, corticosteroids were shown not to be associated with ICU mortality (OR: 1.0; 95% CI: 0.98–1.15). Corticosteroids were administered in 298/537 (55.5%) patients of “A” phenotype and their use was not associated with ICU mortality (HR = 0.85 [0.55–1.33]). A total of 338/623 (54.2%) patients in “B” phenotype received corticosteroids. No effect of corticosteroids on ICU mortality was observed when HR was performed (0.72 [0.49–1.05]). Finally, 535/857 (62.4%) patients in “C” phenotype received corticosteroids. In this phenotype HR (0.75 [0.58–0.98]) and sHR (0.79 [0.63–0.98]) suggest a protective effect of corticosteroids on ICU mortality. Conclusion: Our finding warns against the widespread use of corticosteroids in all critically ill patients with COVID-19 at moderate dose. Only patients with the highest inflammatory levels could benefit from steroid treatment.</dc:description>
<dc:date>2023</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:identifier>Moreno G, Ruiz-Botella M, Martín-Loeches I, Alvarez JG, Herrera MJ, Bodí M, et al. A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients. Med Intensiva. 2023 Jan; 47(1): 23-33. DOI: 10.1016/j.medin.2021.10.002</dc:identifier>
<dc:identifier>0210-5691</dc:identifier>
<dc:identifier>http://hdl.handle.net/10230/53634</dc:identifier>
<dc:identifier>http://dx.doi.org/10.1016/j.medin.2021.10.002</dc:identifier>
<dc:language>eng</dc:language>
<dc:rights>info:eu-repo/semantics/embargoedAccess</dc:rights>
<dc:rights>© Elsevier http://dx.doi.org/10.1016/j.medin.2021.10.002</dc:rights>
<dc:publisher>Elsevier</dc:publisher>
</ow:Publication>
</rdf:RDF>
<?xml version="1.0" encoding="UTF-8" ?>
<metadata schemaLocation="http://www.lyncode.com/xoai http://www.lyncode.com/xsd/xoai.xsd">
<element name="dc">
<element name="contributor">
<element name="author">
<element name="none">
<field name="value">Moreno, Gerard</field>
<field name="value">Marin Corral, Judith</field>
<field name="value">Rodríguez, Alejandro</field>
<field name="value">COVID-19 SEMICYUC Working Group</field>
</element>
</element>
</element>
<element name="date">
<element name="accessioned">
<element name="none">
<field name="value">2022-06-29T07:06:15Z</field>
</element>
</element>
<element name="issued">
<element name="none">
<field name="value">2023</field>
</element>
</element>
<element name="embargoEnd">
<element name="none">
<field name="value">info:eu-repo/date/embargoEnd/2022-10-26</field>
</element>
</element>
</element>
<element name="identifier">
<element name="citation">
<element name="none">
<field name="value">Moreno G, Ruiz-Botella M, Martín-Loeches I, Alvarez JG, Herrera MJ, Bodí M, et al. A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients. Med Intensiva. 2023 Jan; 47(1): 23-33. DOI: 10.1016/j.medin.2021.10.002</field>
</element>
</element>
<element name="issn">
<element name="none">
<field name="value">0210-5691</field>
</element>
</element>
<element name="uri">
<element name="none">
<field name="value">http://hdl.handle.net/10230/53634</field>
</element>
</element>
<element name="doi">
<element name="none">
<field name="value">http://dx.doi.org/10.1016/j.medin.2021.10.002</field>
</element>
</element>
</element>
<element name="description">
<element name="abstract">
<element name="none">
<field name="value">Objective: To determine if the use of corticosteroids was associated with Intensive Care Unit (ICU) mortality among whole population and pre-specified clinical phenotypes. Design: A secondary analysis derived from multicenter, observational study. Setting: Critical Care Units. Patients: Adult critically ill patients with confirmed COVID-19 disease admitted to 63 ICUs in Spain. Interventions: Corticosteroids vs. no corticosteroids. Main variables of interest: Three phenotypes were derived by non-supervised clustering analysis from whole population and classified as (A: severe, B: critical and C: life-threatening). We performed a multivariate analysis after propensity optimal full matching (PS) for whole population and weighted Cox regression (HR) and Fine-Gray analysis (sHR) to assess the impact of corticosteroids on ICU mortality according to the whole population and distinctive patient clinical phenotypes. Results: A total of 2017 patients were analyzed, 1171 (58%) with corticosteroids. After PS, corticosteroids were shown not to be associated with ICU mortality (OR: 1.0; 95% CI: 0.98–1.15). Corticosteroids were administered in 298/537 (55.5%) patients of “A” phenotype and their use was not associated with ICU mortality (HR = 0.85 [0.55–1.33]). A total of 338/623 (54.2%) patients in “B” phenotype received corticosteroids. No effect of corticosteroids on ICU mortality was observed when HR was performed (0.72 [0.49–1.05]). Finally, 535/857 (62.4%) patients in “C” phenotype received corticosteroids. In this phenotype HR (0.75 [0.58–0.98]) and sHR (0.79 [0.63–0.98]) suggest a protective effect of corticosteroids on ICU mortality. Conclusion: Our finding warns against the widespread use of corticosteroids in all critically ill patients with COVID-19 at moderate dose. Only patients with the highest inflammatory levels could benefit from steroid treatment.</field>
</element>
</element>
<element name="provenance">
<element name="en">
<field name="value">Made available in DSpace on 2022-06-29T07:06:15Z (GMT). No. of bitstreams: 1 moreno-mei-adif.pdf: 797198 bytes, checksum: 56849396de860830e4e708ecce55e641 (MD5) Previous issue date: 2021</field>
</element>
</element>
</element>
<element name="format">
<element name="mimetype">
<element name="none">
<field name="value">application/pdf</field>
</element>
</element>
</element>
<element name="language">
<element name="iso">
<element name="none">
<field name="value">eng</field>
</element>
</element>
</element>
<element name="publisher">
<element name="none">
<field name="value">Elsevier</field>
</element>
</element>
<element name="rights">
<element name="none">
<field name="value">© Elsevier http://dx.doi.org/10.1016/j.medin.2021.10.002</field>
</element>
<element name="accessRights">
<element name="none">
<field name="value">info:eu-repo/semantics/embargoedAccess</field>
</element>
</element>
</element>
<element name="title">
<element name="none">
<field name="value">A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients</field>
</element>
</element>
<element name="type">
<element name="none">
<field name="value">info:eu-repo/semantics/article</field>
</element>
<element name="version">
<element name="none">
<field name="value">info:eu-repo/semantics/acceptedVersion</field>
</element>
</element>
</element>
<element name="subject">
<element name="keyword">
<element name="none">
<field name="value">COVID-19</field>
<field name="value">Corticosteroids</field>
<field name="value">ICU Mortality</field>
<field name="value">Phenotypes</field>
<field name="value">SARS-CoV2-pneumonia</field>
<field name="value">Unsupervised clustering</field>
</element>
</element>
</element>
<element name="embargo">
<element name="liftdate">
<element name="none">
<field name="value">2022-10-26</field>
</element>
</element>
</element>
</element>
<element name="bundles">
<element name="bundle">
<field name="name">THUMBNAIL</field>
<element name="bitstreams">
<element name="bitstream">
<field name="name">moreno-mei-adif.pdf.jpg</field>
<field name="originalName">moreno-mei-adif.pdf.jpg</field>
<field name="description">IM Thumbnail</field>
<field name="format">image/jpeg</field>
<field name="size">14273</field>
<field name="url">http://repositori.upf.edu/bitstream/10230/53634/3/moreno-mei-adif.pdf.jpg</field>
<field name="checksum">c50569c5eab303764c34e78ca6e43d7d</field>
<field name="checksumAlgorithm">MD5</field>
<field name="sid">3</field>
</element>
</element>
</element>
<element name="bundle">
<field name="name">TEXT</field>
<element name="bitstreams">
<element name="bitstream">
<field name="name">moreno-mei-adif.pdf.txt</field>
<field name="originalName">moreno-mei-adif.pdf.txt</field>
<field name="description">Extracted text</field>
<field name="format">text/plain</field>
<field name="size">52424</field>
<field name="url">http://repositori.upf.edu/bitstream/10230/53634/2/moreno-mei-adif.pdf.txt</field>
<field name="checksum">840d423b5ad467fd5867e5c2282bb06f</field>
<field name="checksumAlgorithm">MD5</field>
<field name="sid">2</field>
</element>
</element>
</element>
<element name="bundle">
<field name="name">ORIGINAL</field>
<element name="bitstreams">
<element name="bitstream">
<field name="name">moreno-mei-adif.pdf</field>
<field name="format">application/pdf</field>
<field name="size">797198</field>
<field name="url">http://repositori.upf.edu/bitstream/10230/53634/1/moreno-mei-adif.pdf</field>
<field name="checksum">56849396de860830e4e708ecce55e641</field>
<field name="checksumAlgorithm">MD5</field>
<field name="sid">1</field>
</element>
</element>
</element>
</element>
<element name="others">
<field name="handle">10230/53634</field>
<field name="identifier">oai:repositori.upf.edu:10230/53634</field>
<field name="lastModifyDate">2023-03-06 08:25:22.802</field>
</element>
<element name="repository">
<field name="name">Repositori digital de la UPF</field>
<field name="mail">repositori@upf.edu</field>
</element>
</metadata>